Rotigotine
As of the edition of 20 October 2026, Rotigotine is a small molecule: marketed, first approved in 2006 (EU); acts on DRD2, DRD3 and DRD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Neupro
- First approved
- 15 February 2006 (EU)
- Approvals on record
- 9 in 4 regions
- Holder of the most recent approval
- UCB; 4 holders in all
- Registered trials
- 79, 7 stopped early
- Disease areas
- Nervous system; Mental health; Bones, joints and muscles; Chemically induced; Heart and blood vessels; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Rotigotine.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 3 | 1 | 0 |
| Phase 1 | 14 | 13 | 0 | 1 |
| Phase 2 | 17 | 15 | 0 | 1 |
| Phase 3 | 32 | 26 | 1 | 4 |
| Phase 4 | 10 | 9 | 0 | 1 |
| All trials | 79 |